scholarly journals TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients

2010 ◽  
Vol 33 (1) ◽  
pp. 1-11 ◽  
Author(s):  
A. Fariña-Sarasqueta ◽  
M. J. E. M. Gosens ◽  
E. Moerland ◽  
I. van Lijnschoten ◽  
V. E. P. P. Lemmens ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Colon Carcinoma ◽  
Gene Polymorphisms ◽  
Tandem Repeats ◽  
Therapy Response ◽  
Positive Association ◽  
Variable Number ◽  
Stage Iii ◽  
Predictive And Prognostic Value

Aim: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.Patients and Methods: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected. The variable number of tandem repeats (VNTR) and the single nucleotide polymorphism (SNP) in the 5′-untranslated region of the TS gene were genotyped.Results: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05). In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found. However, there was an association between both polymorphisms and age. Among patients younger than 60 years, the patients homozygous for 2R seemed to have a better overall survival, whereas among the patients older than 67 this longer survival was seen by the carriers of other genotypes.Conclusion: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma. However, age appears to modify the effects of TS polymorphisms on survival.

scholarly journals Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

2010 ◽  
Vol 66 (6) ◽  
pp. 1167-1171 ◽  
Author(s):  
Arantza Fariña-Sarasqueta ◽  
Gesina van Lijnschoten ◽  
Harm J. T. Rutten ◽  
Adriaan J. C. van den Brule
Keyword(s):  
Pilot Study ◽  
Colon Carcinoma ◽  
Gene Polymorphisms ◽  
Therapy Response ◽  
Stage Iii

Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms

2019 ◽  
Vol 51 (8) ◽  
pp. 1198-1201
Author(s):  
Anthony Turpin ◽  
Julien Labreuche ◽  
Jean-François Fléjou ◽  
Thierry Andre ◽  
Aimery de Gramont ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Gene Polymorphisms ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Underlying Susceptibility to Eating Disorders and Drug Abuse: Genetic and Pharmacological Aspects of Dopamine D4 Receptors

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2288 ◽  
Author(s):  
Luca Botticelli ◽  
Emanuela Micioni Di Bonaventura ◽  
Fabio Del Bello ◽  
Gianfabio Giorgioni ◽  
Alessandro Piergentili ◽  
...  
Keyword(s):  
Drug Abuse ◽  
Eating Behaviors ◽  
Tandem Repeats ◽  
Drugs Of Abuse ◽  
Brain Area ◽  
Variable Number ◽  
Intracellular Response ◽  
D4 Receptor ◽  
Maladaptive Eating

The dopamine D4 receptor (DRD4) has a predominant expression in the prefrontal cortex (PFC), brain area strictly involved in the modulation of reward processes related to both food and drug consumption. Additionally, the human DRD4 gene is characterized by a variable number of tandem repeats (VNTR) in the exon 3 and, among the polymorphic variants, the 7-repeat (7R) allele appears as a contributing factor in the neurobiological mechanisms underlying drug abuse, aberrant eating behaviors and related comorbidities. The 7R variant encodes for a receptor with a blunted intracellular response to dopamine, and carriers of this polymorphism might be more tempted to enhance dopamine levels in the brain, through the overconsumption of drugs of abuse or palatable food, considering their reinforcing properties. Moreover, the presence of this polymorphism seems to increase the susceptibility of individuals to engage maladaptive eating patterns in response to negative environmental stimuli. This review is focused on the role of DRD4 and DRD4 genetic polymorphism in these neuropsychiatric disorders in both clinical and preclinical studies. However, further research is needed to better clarify the complex DRD4 role, by using validated preclinical models and novel compounds more selective for DRD4.

scholarly journals The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection

2018 ◽  
Vol 29 ◽  
pp. viii180
Author(s):  
S.-H. Cho ◽  
H.-J. Shim ◽  
J.E. Hwang ◽  
W.-K. Bae ◽  
I.J. Chung
Keyword(s):  
Colon Cancer ◽  
Curative Resection ◽  
Stage Iii ◽  
Prognostic Role ◽  
Stage Iii Colon Cancer

scholarly journals The Role of Tumor Deposits in Predicting the Efficacy of Chemotherapy in Stage III Colon Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Mingyu Shi ◽  
Hongzhi Zhang ◽  
Guozhong Yao ◽  
Jianjun Wu ◽  
Chuming Zhu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

The role of early postoperative PET-CT in patients with pathological stage III colon cancer: Results from a large single institution study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 562-562
Author(s):  
Assaf Moore ◽  
Irit Ben-Aharon ◽  
Ofer Purim ◽  
Gali Perl ◽  
Olga Ulitsky ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Nodes ◽  
Metastatic Disease ◽  
Stage Iii ◽  
Individual Risk ◽  
Pathological Stage ◽  
Stage Iii Colon Cancer ◽  
Pet Ct

562 Background: Current staging of patients (pts) with pathological stage III colon cancer is suboptimal; many pts still recur despite unremarkable preoperative staging work-up. We previously reported that early postoperative PET-CT can alter the stage and management of pts with high risk stage III colon cancer in up to 19% of patients. The aim of the current study was to expand the previous one to a larger cohort and to determine the role of early postoperative PET-CT in the general population of stage III colon cancer pts, regardless of their individual risk. Methods: A retrospective chart review of all consecutive pts with stage III colon cancer who underwent early postoperative PET-CT between 2007 and 2016. Demographic and clinicopathological data were collected. Results: 247 pts, 124 (50%) males, with a median age of 66 years (range, 30-92), were included. Pathological stage was IIIA, IIIB and IIIC in 18 (7.3%), 161 (65.1%) and 72 (29.1%) pts, respectively. The median number of lymph nodes retrieved was 15 (range, 6-64) and that of positive lymph nodes was 2 (range, 0-21). High FDG-uptake was observed in 52 (21.0%) pts, including 6 (2.4%) who had clear postoperative changes, 10 (4.0%) who had a false positive abnormal uptake of whom 6 underwent invasive diagnostic procedures. The PET-CT results modified the management of 36 pts (14.5%) who were found to have true positive findings: 30 (12.1%) were proven to have overt metastatic disease and in 6 (2.4%) a second primary was discovered. With the median follow-up of 39.0 months (range 7.2-98.4 months), of the 30 pts found to be metastatic, 10 (33.3%) underwent curative treatments and are currently with no evidence of disease (NED). Updated data, on more patients and a longer follow-up, will be presented at the meeting. Conclusions: Early postoperative PET-CT changed the staging and treatment of 14.5% of resected stage III pts, and has the potential for early detection of curable metastatic disease. We currently evaluate this strategy and its actual impact in a prospective trial.

scholarly journals Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

JAMA Oncology ◽  
2018 ◽  
Vol 4 (3) ◽  
pp. 379 ◽  
Author(s):  
Aziz Zaanan ◽  
Qian Shi ◽  
Julien Taieb ◽  
Steven R. Alberts ◽  
Jeffrey P. Meyers ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Mismatch Repair ◽  
Dna Mismatch Repair ◽  
Stage Iii ◽  
Dna Mismatch ◽  
Stage Iii Colon Cancer ◽  
Mismatch Repair Status

Survival after adjuvant 5-FU treatment for stage III colon cancer: Possible role of mismatch repair (MMR) gene defect

2003 ◽  
Vol 124 (4) ◽  
pp. A550-A551
Author(s):  
Wouter H. De Vos ◽  
Hielke J. Meulebeld ◽  
Jan H. Kleibeuker ◽  
Fokko M. Nagengast ◽  
Fred H. Menko ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Mismatch Repair ◽  
Stage Iii ◽  
Gene Defect ◽  
Stage Iii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document